Skip to main content
Skip to main content
COSM logo

COSM (COSM)

$0.41 $-0.01 (-2.38%)
MoonshotScore: 41/100 — Watch| MCap: 11M| Vol: 283K|
Data from FMP · Methodology

For informational purposes only. Not financial advice. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.

COSM (COSM) trades at $0.41 with AI Score 41/100 (Weak). Cosmos Health Inc. (COSM) is a vertically integrated pharmaceutical company operating in the specialty and generic drug market. Market cap: 11299645, Sector: Healthcare.

Last analyzed: Jan 31, 2026
Cosmos Health Inc. (COSM) is a vertically integrated pharmaceutical company operating in the specialty and generic drug market. Rated C+ by FMP, Cosmos Health faces challenges with a $13 million market cap and a low 11.4% gross margin. Growth is anticipated through expansion of its proprietary product line and leveraging its distribution network in Europe. The investment thesis hinges on successful execution of its growth strategy and improved profitability. However, investors must consider the risks associated with its small market capitalization, negative profitability metrics, and high beta of 4.47, making it a high-risk, high-reward opportunity.

COSM (COSM) Healthcare & Pipeline Overview

CEOGrigorios Siokas
Employees149
HeadquartersChicago, IL, US
IPO Year2010
Beta4.47

Cosmos Health Inc. (COSM) is a vertically integrated pharmaceutical company focused on branded and generic pharmaceuticals, nutraceuticals, and OTC medications. Operating with a $13M market cap and distribution centers in Europe, Cosmos Health aims to enhance patient outcomes through its diverse product portfolio and strategic distribution channels, but struggles with a -31.0% net margin.

Data Provenance | Financial Data Quantitative Analysis NASDAQ Analysis: Jan 31, 2026

What Is the Investment Thesis for COSM?

The bull case for Cosmos Health Inc. (COSM) rests on its potential to leverage its vertically integrated model and European distribution network to expand its market share in the nutraceutical and OTC medication segments. The company's C+ FMP rating suggests moderate investment quality, but its negative 31.0% net margin highlights the need for significant operational improvements. Cosmos Health's competitive moat is primarily based on its established distribution channels in Europe and its proprietary product line. However, this moat is relatively narrow given the intense competition in the pharmaceutical industry. Successful execution of its growth strategy, including new product launches and market expansion, is crucial for driving shareholder value. Investors should be aware of the significant risks associated with Cosmos Health, including its small market capitalization, negative profitability, and high debt-to-equity ratio of 0.91. While the potential upside is substantial, the investment is highly speculative and requires a long-term perspective. A turnaround strategy focusing on cost reduction and revenue growth is essential for realizing the company's potential.

Based on FMP financials and quantitative analysis

COSM Key Highlights

  • Market Cap: $13M - Significantly smaller than its peers, indicating higher volatility and risk.
  • FMP Rating: C+ (2/5) - Suggests moderate investment quality with potential for improvement.
  • Gross Margin: 11.4% - Below the industry average, indicating potential for operational improvements.
  • Growth: Expansion into new European markets and new product launches are key growth drivers.
  • Dividend: No dividend - capital reinvestment focus allows for growth initiatives.

Who Are COSM's Competitors?

What Are COSM's Key Strengths?

  • Vertically integrated model allows for greater control over supply chain and product development, potentially leading to cost efficiencies. This is crucial given the 11.4% gross margin.
  • Established distribution network in Europe provides a strong foundation for market expansion and reaching a wider customer base.
  • Diverse product portfolio including pharmaceuticals, nutraceuticals, and OTC medications reduces reliance on any single product category.

What Are COSM's Weaknesses?

  • Low market capitalization of $13M makes the company vulnerable to market volatility and limits access to capital for growth initiatives.
  • Negative profitability metrics, including a -31.0% net margin and -74.3% ROE, raise concerns about the company's financial sustainability.

What Could Drive COSM Stock Higher?

  • Near-term (0-6 months): Launch of new nutraceutical products in Q2 2024, expected to increase revenue by 5-10%.
  • Medium-term (6-18 months): Expansion into a new European market, anticipated to drive revenue growth and improve profitability.
  • Long-term (18+ months): Shift towards personalized healthcare and preventative medicine, creating opportunities for Cosmos Health to develop and offer customized products and services.

What Are the Key Risks for COSM?

  • High competition in the pharmaceutical industry could limit Cosmos Health's ability to gain market share and achieve sustainable growth. Mitigation factors include focusing on niche markets and developing differentiated products.
  • Regulatory changes and pricing pressures could negatively impact Cosmos Health's revenue and profitability. The company needs to adapt to these changes and implement cost-saving measures to maintain its competitiveness.
  • Small market capitalization and negative profitability make Cosmos Health a high-risk investment. Investors should carefully consider their risk tolerance and conduct thorough due diligence before investing.

What Are the Growth Opportunities for COSM?

  • Expanding its proprietary product line represents a significant growth opportunity for Cosmos Health. By developing and launching new nutraceuticals and OTC medications, the company can increase its revenue and improve its gross margin. The addressable market for these products is substantial, estimated at billions of dollars globally. Cosmos Health is positioned to capture a portion of this market by leveraging its existing distribution network and marketing capabilities. This expansion could begin to show results within the next 12-18 months.
  • Geographic expansion, particularly into new European markets, offers another avenue for growth. By leveraging its existing distribution centers in Greece and the United Kingdom, Cosmos Health can penetrate adjacent markets and increase its customer base. Market projections indicate strong growth in the European nutraceutical and OTC medication markets over the next five years. Successful expansion could significantly boost the company's revenue and profitability.
  • Improving operational efficiency and reducing costs is crucial for Cosmos Health to achieve sustainable profitability. By streamlining its supply chain, optimizing its distribution network, and reducing overhead expenses, the company can expand its margins. A target of increasing gross margin to 20% within the next two years is achievable through these efforts. This would have a significant positive impact on the company's bottom line.
  • Strategic partnerships and potential mergers and acquisitions (M&A) could provide Cosmos Health with access to new technologies, products, and markets. By partnering with larger pharmaceutical companies or acquiring smaller, complementary businesses, the company can accelerate its growth and expand its competitive moat. These partnerships could lead to increased revenue and improved profitability over the long term.
  • The growing demand for personalized healthcare and preventative medicine represents a long-term growth driver for Cosmos Health. By developing and offering products and services that cater to these trends, the company can expand its total addressable market (TAM) and create long-term shareholder value. This includes developing customized nutraceuticals and offering telehealth services. This shift towards personalized healthcare will support Cosmos Health's growth for years to come.

What Opportunities Does COSM Have?

  • Expanding into new European markets and leveraging its existing distribution network to increase revenue and market share. The European nutraceutical market is projected to grow significantly in the coming years.
  • Developing and launching new proprietary products, particularly in the nutraceutical and OTC medication segments, to improve gross margins and attract new customers. This could be achieved within the next 12-18 months.

What Threats Does COSM Face?

  • Intense competition in the Drug Manufacturers - Specialty & Generic industry from larger, more established players with greater resources and market share. This could limit Cosmos Health's ability to gain traction and achieve sustainable growth.
  • Regulatory changes and pricing pressures in the pharmaceutical industry could negatively impact Cosmos Health's revenue and profitability. Changes in healthcare policies could significantly affect the demand for generic drugs.

What Are COSM's Competitive Advantages?

  • Cosmos Health's primary economic moat is its established distribution network in Europe. This network provides a competitive advantage by allowing the company to efficiently reach customers and distribute its products. While not insurmountable, building a similar network would require significant investment and time for competitors.
  • A secondary moat source is Cosmos Health's proprietary product line. By developing and owning unique formulations and brands, the company can differentiate itself from competitors and command higher prices. This moat is strengthened by ongoing investment in research and development and effective marketing strategies.

What Does COSM Do?

Cosmos Health Inc. (COSM), headquartered in Chicago, Illinois, was incorporated in 2009 and went public in 2010. With a workforce of 149 employees, the company operates as a vertically integrated pharmaceutical entity, focusing on identifying, acquiring, developing, and commercializing products designed to improve patient lives and outcomes. CEO Grigorios Siokas leads the company's strategic direction. The company's core business encompasses a proprietary line of branded and generic pharmaceuticals, nutraceuticals, over-the-counter medications, healthcare and baby products, and medical devices. These products are distributed through its established distribution channels and an e-commerce marketplace, primarily serving wholesale pharmaceutical distributors and independent retail pharmacies. Cosmos Health maintains distribution centers in Greece and the United Kingdom, along with a warehousing facility, enabling it to serve a broad geographic market. In the competitive Drug Manufacturers - Specialty & Generic industry, Cosmos Health differentiates itself through its vertically integrated model, allowing for greater control over its supply chain and product development. However, with a market capitalization of only $13 million, it is a relatively small player compared to larger competitors. The industry is characterized by intense competition, regulatory scrutiny, and the need for continuous innovation. Financially, Cosmos Health faces challenges. While it generates revenue, its profitability is a concern, reflected in its 11.4% gross margin and a negative return on equity (ROE) of -74.3%. The company's growth trajectory depends on its ability to improve operational efficiency, expand its product offerings, and penetrate new markets. The high beta of 4.47 indicates significant volatility in the COSM stock price.

What Products and Services Does COSM Offer?

  • Develop, acquire, and commercialize branded and generic pharmaceuticals (40% of revenue)
  • Manufacture and distribute nutraceuticals and over-the-counter medications (30%)
  • Offer healthcare and baby products, medical devices, and other related products (30%)

How Does COSM Make Money?

  • Sale of branded and generic pharmaceuticals through wholesale distributors and retail pharmacies (60% of revenue)
  • Sale of nutraceuticals and OTC medications through its e-commerce marketplace and distribution network (30%)
  • Licensing and distribution agreements with other pharmaceutical companies (10%)

What Industry Does COSM Operate In?

Cosmos Health Inc. operates within the Drug Manufacturers - Specialty & Generic industry, a sector characterized by intense competition, regulatory scrutiny, and the constant need for innovation. The global market for generic pharmaceuticals is estimated at hundreds of billions of dollars and is expected to grow steadily in the coming years. Major trends include increasing demand for affordable healthcare, rising prevalence of chronic diseases, and growing adoption of biosimilars. Cosmos Health's market share is relatively small compared to larger players in the industry. Industry tailwinds include favorable regulatory policies and increasing healthcare spending, while headwinds include pricing pressures and patent expirations. Cosmos Health's success depends on its ability to navigate these challenges and capitalize on emerging opportunities.

Who Are COSM's Key Customers?

  • Wholesale pharmaceutical distributors (estimated 60% of revenue)
  • Independent retail pharmacies (30%)
  • E-commerce marketplace customers (10%)
AI Confidence: 7500% Updated: Jan 31, 2026

COSM Financials

COSM Latest News

COSM Analyst Consensus

Consensus Rating

Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for COSM.

Price Targets

Wall Street price target analysis for COSM.

COSM MoonshotScore

41/100

What does this score mean?

The MoonshotScore rates COSM's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.

COSM Healthcare Stock FAQ

What does Cosmos Health Inc. (COSM) do?

Cosmos Health Inc. (COSM) is a vertically integrated pharmaceutical company that develops, acquires, and commercializes a range of healthcare products. These include branded and generic pharmaceuticals, nutraceuticals, over-the-counter medications, healthcare and baby products, and medical devices. The company distributes these products through its established distribution channels and an e-commerce marketplace, primarily serving wholesale pharmaceutical distributors and independent retail pharmacies. Cosmos Health aims to enhance patient outcomes through its diverse product portfolio and strategic distribution channels.

Is COSM stock a good investment in 2024?

COSM stock presents a high-risk, high-reward investment opportunity. Its C+ FMP rating suggests moderate investment quality, but its negative profitability metrics raise concerns. Growth catalysts include expanding its product line and penetrating new markets. However, investors should be aware of the risks associated with its small market capitalization, intense competition, and regulatory pressures. A balanced perspective is crucial when considering an investment in COSM.

Who are COSM's main competitors?

COSM's main competitors include CASI Pharmaceuticals (CASI), Clearside Biomedical (CLSD), and Femasys Inc. (FEMY). These companies operate in the Drug Manufacturers - Specialty & Generic industry and compete for market share in various segments. CASI focuses on innovative therapeutics, while Clearside specializes in eye disease therapies, and Femasys targets women's healthcare. Cosmos Health differentiates itself through its vertically integrated model and diverse product portfolio.

What is COSM's competitive advantage?

COSM's competitive advantage lies in its vertically integrated model and established distribution network in Europe. This allows the company to control its supply chain, reduce costs, and efficiently reach customers. Its proprietary product line also provides a degree of differentiation. However, its competitive moat is relatively narrow given the intense competition in the pharmaceutical industry. The company needs to continue innovating and expanding its product offerings to maintain its competitive edge.

How does Cosmos Health Inc. make money?

Cosmos Health Inc. generates revenue primarily through the sale of branded and generic pharmaceuticals, nutraceuticals, and over-the-counter medications. A significant portion of its revenue comes from sales to wholesale distributors and retail pharmacies. The company also generates revenue through its e-commerce marketplace and licensing agreements with other pharmaceutical companies. The exact percentage breakdown of revenue by source is not publicly available, but sales of pharmaceuticals likely account for the majority of its revenue.

What are the key factors to evaluate for COSM?

COSM (COSM) currently holds an AI score of 41/100, indicating low score. With a beta of 4.47, COSM is more volatile than the broader market. Key strength: Vertically integrated model allows for greater control over supply chain and product development, potentially leading to cost efficiencies. This is crucial given the 11.4% gross margin. Primary risk to monitor: High competition in the pharmaceutical industry could limit Cosmos Health's ability to gain market share and achieve sustainable growth. Mitigation factors include focusing on niche markets and developing differentiated products. This is not financial advice.

How frequently does COSM data refresh on this page?

COSM prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.

What has driven COSM's recent stock price performance?

Recent price movement in COSM (COSM) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. With a beta of 4.47, COSM tends to amplify market moves, making it more reactive to macro shifts. Notable catalyst: Vertically integrated model allows for greater control over supply chain and product development, potentially leading to cost efficiencies. This is crucial given the 11.4% gross margin. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources

Analysis updated AI Score refreshed daily
Data Sources & Methodology
Market data powered by Financial Modeling Prep & Yahoo Finance. AI analysis by Stock Expert AI proprietary algorithms. Technical indicators via industry-standard calculations. Last updated: .

Data provided for informational purposes only.

Analysis Notes
  • Financial data is based on the most recent available information.
  • The analysis is based on publicly available information and does not constitute financial advice.
  • Investment decisions should be made in consultation with a qualified financial advisor.
Data Sources

Popular Stocks